Voranigo (vorasidenib) — United Healthcare
Oligodendroglioma
Initial criteria
- One of the following diagnoses: Astrocytoma OR Oligodendroglioma
- Presence of IDH1 or IDH2 mutation
- History of one of the following: Biopsy OR Sub-total resection OR Gross total resection
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Voranigo therapy
Approval duration
12 months